New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?

Abstract

The barrier of iatrogenic hypoglycaemia has limited the utility and safety of conventional diabetes medications. Novel agents for type 2 diabetes aim to surmount the impediment of iatrogenic hypoglycaemia and unmask the full realisation and benefits of achieving sustained euglycaemia over a lifetime of diabetes. This review aims to critically consider the risk of iatrogenic hypoglycaemia allied with newer agents for type 2 diabetes, used alone and in combination with other diabetes therapies, and how this risk can be minimised. Copyright © 2015 John Wiley & Sons. Copyright © 2015 John Wiley & Sons, Ltd.